Results 21 to 30 of about 28,958 (244)

Relationship between plasma dabigatran concentration and activated partial thromboplastin time in Japanese patients with non-valvular atrial fibrillation

Journal of Arrhythmia, 2015
Background: Activated partial thromboplastin time (aPTT) is recommended for monitoring anticoagulant activity in dabigatran-treated patients; however, there are limited data in Japanese patients.
Daiki Shimomura, Yoshihisa Nakagawa, MD, Hirokazu Kondo, MD, Toshihiro Tamura, MD, Masashi Amano, MD, Yukiko Hayama, MD, Naoaki Onishi, MD, Yodo Tamaki, MD, Makoto Miyake, MD, Kazuaki Kaitani, MD, Chisato Izumi, MD, Masahiko Hayashida, Aya Fukuda, Fumihiko Nakamura, MD, Seiji Kawano, MD   +14 more
doaj   +1 more source

Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study

European Heart Journal - Cardiovascular Pharmacotherapy, 2020
Aims The aim of this study was to compare the risk of stroke or systemic embolism (SE) and major bleeding in patients with atrial fibrillation (AF) using dabigatran, rivaroxaban, and apixaban in routine clinical practice.
O. Rutherford, C. Jonasson, W. Ghanima, F. Söderdahl, S. Halvorsen   +4 more
semanticscholar   +1 more source

Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis

JAMA Neurology, 2019
Key Points Question Is dabigatran etexilate or dose-adjusted warfarin efficacious and safe to use in preventing the recurrence of venous thrombotic events among patients with cerebral venous thrombosis? Findings In this exploratory randomized, open-label
J. Ferro, J. Coutinho, F. Dentali, A. Kobayashi, A. Alasheev, P. Canhão, D. Karpov, S. Nagel, Laura Posthuma, J. Roriz, Jorge Caria, Mandy Fräßdorf, Holger Huisman, P. Reilly, H. Diener   +14 more
semanticscholar   +1 more source

Dabigatran etexilate tetrahydrate [PDF]

Acta Crystallographica Section E Structure Reports Online, 2012
In the title compound, C34H41N7O5·4H2O (systematic name: ethyl 3-{[2-({4-[(Z)-amino-(hexyl-oxycarbonyl-imino)-meth-yl]anilino}meth-yl)-1-meth-yl-benzimidazole-5-carbon-yl]pyridin-2-yl-amino}-propano-ate tetra-hydrate), the benzene and pyridine rings form dihedral angles of 5.4 (1) and 43.8 (1)°, respectively, with the benzimidazole mean plane.
Hong-Qiang Liu, Wei-Guang Zhang, Zhi-Qiang Cai, Wei-Ren Xu, Xiu-Ping Shen   +4 more
openaire   +3 more sources

Thrombocytopenia induced by dabigatran: two case reports

BMC Neurology, 2017
Background Vitamin K inhibitors (e.g. warfarin) and indirect thrombin inhibitors (e.g. heparin) are widely used to prevent thromboembolic disorders (e.g. myocardial infarction, venous thromboembolism, and stroke).
Hyun Goo Kang, Seung Jae Lee, Ji Yeon Chung, Jin Sung Cheong   +3 more
doaj   +1 more source

HOW TO USE DABIGATRAN IN PATIENTS WITH ATRIAL FIBRILLATION

Рациональная фармакотерапия в кардиологии, 2015
Dabigatran is the new oral anticoagulant that directly inhibits thrombin (factor IIa). In RE-LY clinical trial dabigatran 150 mg b.i.d was more effective than warfarin in prevention of ischemic stroke and systemic embolic events in more than 18000 ...
S. V. Moiseev
doaj   +3 more sources

Effect of Dabigatran on Clotting Time in the Clotpro Ecarin Clotting Assay: A Prospective, Single-Arm, Open-Label Study

Clinical and Applied Thrombosis/Hemostasis, 2020
Routine coagulation tests do not enable rapid, accurate determination of direct oral anticoagulant (DOAC) therapy. The ecarin clotting assay (ECA), performed on the ClotPro viscoelastic testing device, may enable sensitive and specific detection of ...
Alan Yean Yip Fong MRCP, Lee Len Tiong BPharm, Shirley Siang Ning Tan BPharm, Dominic Geruka BSc, Gerald Grino Apil BSc, Chee Wei Choo MSc, Tiong Kiam Ong MRCP   +6 more
doaj   +1 more source

Use of Continuous Renal Replacement Therapy for Removal of Dabigatran in a Patient in Need of Emergent Surgery

Case Reports in Critical Care, 2016
Purpose. To report the ability to remove serum dabigatran using continuous renal replacement therapy (CRRT) in a patient with life-threatening bleeding. Summary.
Sara E. Parli, Melissa L. Thompson Bastin, Daniel A. Lewis   +2 more
doaj   +1 more source

Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial.

The Lancet, 2018
BACKGROUND Myocardial injury after non-cardiac surgery (MINS) increases the risk of cardiovascular events and deaths, which anticoagulation therapy could prevent. Dabigatran prevents perioperative venous thromboembolism, but whether this drug can prevent
P. Devereaux, E. Duceppe, G. Guyatt, V. Tandon, R. Rodseth, B. Biccard, D. Xavier, W. Szczeklik, C. Meyhoff, J. Vincent, M. Franzosi, S. Srinathan, J. Erb, P. Magloire, J. Neary, Mangala Rao, P. Rahate, N. Chaudhry, B. Mayosi, M. Nadal, P. P. Iglesias, O. Berwanger, J. Villar, F. Botto, J. Eikelboom, D. Sessler, C. Kearon, S. Pettit, Mukul Sharma, S. Connolly, S. Bangdiwala, P. Rao-Melacini, A. Hoeft, S. Yusuf, P. Devereaux, S. Bangdiwala, S. Connolly, J. Eikelboom, J. Pogue, D. Sessler, Sara Di Diodato, Zora Gasic, Louise Mastrangelo, S. Molnar, J. L. Swanson, Makayla Tosh, James Ingram Wells, R. Diaz, C. Chow, B. Gonzales, S. Vásquez, P. Janský, Radovan Dušek, C. Meyhoff, P. Coriat, M. Wittmann, G. Yonga, N. Mathur, Elena Seletti, G. Málaga, B. Tumanan-Mendoza, M. P. Tagle, B. Biccard, P. Alonso-Coello, E. Popova, M. Shields, Y. Manach, P. Moayyedi, S. V. Zanten, E. Fleischmann, A. Garg, K. Karaye, E. McFalls, A. Sigamani, E. Belley‐Cote, G. Biedroń, F. Borges, S. F. Stella, Christian Nielsen, D. Leong, J. Spence, Allen Tran, K. Wawrzycka-Adamczyk, Stephen Yang, Terence Yung, D. Wyse, D. Cheng, D. Johnstone, G. Wells, P. Joseph, Ameen Patel, K. Gregus, Kelly Lawrence, Lindsay Doharris, D. Conen, J. Cheung, J. Douketis, D. Wright, Spencer Wikkerink, W. Dechert, Mohamed Panju, K. Azzam, T. Rapanos, T. Helder, A. Shroff, J. Hare, B. Kidane, T. Nguyen, Larissa Leydier, Vanessa Bayaraa, J. Parlow, Deborah DuMerton, A. Thakrar, Jessica Shelley, B. Deligne, R. Carling, M. Mrkobrada, G. Dresser, M. Jacka, David Hornstein, G. Winkelaar, Z. Haider, Pravina Prashant Lanjewar, Valsamma Varughese, R. Calton, Hemani Ahuja, P. George, Ambika Sharma, K. Bhatt, Dhaval Mangukiya, Karshan Nandaniya, V. Parekh, A. Pillai, V. Menon, S. Desai, R. Sidhu, S. Gupta, R. George, T. R. Gurunath, L. Drummond, A. Torborg, Belinda S. Küsel, P. Naidoo, D. Naidoo, C. Rajah, Z. Farina, R. V. Rahden, S. Gumede, C. Chishala, E. Coetzee, R. Dyer, J. Diedericks, Piotr Bielański, Bogusz Kaczmarek, D. Studzińska, M. Zaniewski, M. Libura, Tomasz Mikołaj Zacharias-Nalichowski, Aurelia Sega, Jakub Salwa, M. Kózka, J. Górka, A. Włudarczyk, I. Nowak-Kózka, P. Grudzień, Jaroslaw W. Gucwa, M. Słowiaczek, P. Dobosz, I. Gögenur, J. R. Eriksen, Tine Borup, T. Kirkegaard, Dan Isbye, Asger Sonne, L. Rasmussen, S. Pedersen, Hannibal Troensegaard, C. Duus, B. Halle, O. Gundel, K. F. Bernholm, K. Martinsen, S. Pedersen, T. Itenov, Elena Camio, C. Vazquez, Silvia Matarín, Esther Cano, J. Álvarez-García, I. India, A. Gonzalez-Osuna, M. Vives, E. Rosselló, A. Serrano, M. Turiel, L. Drago, C. Colombo, F. Marra, L. Mos, Franco Arteni, R. Lembo, A. Ortalda, S. Passarani, Z. Mokini, E. Figueiredo, Gustavo Fonseca Werner, J. L. Petriz, L. Maia, R. Bergo, D. Précoma, J. Saraiva, O. Vilamajó, E. Allegrini, Mariano Benzadón, M. L. Parody, E. Duronto, A. Ingaramo, G. A. Parra, D. Novoa, Scott A. Miller, Sabu Thomas, S. Karlapudi, Mohamad Bourji, Subhash Banerjee, Anita K. Gupta, I. Opole, M. Fischer, V. Mendoza, Eugenio B. Reyes, R. Pierson, M. Shields, V. Piriou, K. Zacharowski, A. Rotta-Rotta, Main Paper, S. Srinathan, P. Rahate, N. Chaudhry, B. Mayosi, Mike Sharma   +239 more
semanticscholar   +1 more source

New indications for dabigatran: A suggestion from a drug use evaluation study

Journal of Research in Pharmacy Practice, 2017
Objective: Dabigatran etexilate is a novel oral anticoagulant with several advantages over warfarin such as no need for routine monitoring and fewer drug interactions. This drug was added to our hospital's formulary in 2012.
Farzaneh Ashrafi, Najmeh Rezaie, Sarah Mousavi   +2 more
doaj   +1 more source